Pipe S - Search Results

1

Expression of factor VIII in recombinant and transgenic systems.

Soukharev S, Hammond D, Ananyeva NM, Anderson JA, Hauser CA, Pipe S, Saenko EL. Soukharev S, et al. Among authors: pipe s. Blood Cells Mol Dis. 2002 Mar-Apr;28(2):234-48. doi: 10.1006/bcmd.2002.0508. Blood Cells Mol Dis. 2002. PMID: 12064919 Review.

2

Molecular defects in coagulation Factor VIII and their impact on Factor VIII function.

Saenko EL, Ananyeva N, Kouiavskaia D, Schwinn H, Josic D, Shima M, Hauser CA, Pipe S. Saenko EL, et al. Among authors: pipe s. Vox Sang. 2002 Aug;83(2):89-96. doi: 10.1046/j.1423-0410.2002.00183.x. Vox Sang. 2002. PMID: 12201837 Free article. Review.

3

Factor VIII therapy for hemophilia A: current and future issues.

Aledort L, Ljung R, Mann K, Pipe S. Aledort L, et al. Among authors: pipe s. Expert Rev Hematol. 2014 Jun;7(3):373-85. doi: 10.1586/17474086.2014.899896. Epub 2014 Apr 10. Expert Rev Hematol. 2014. PMID: 24717090 Review.

4

Emicizumab for hemophilia A with factor VIII inhibitors.

Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Young G, et al. Among authors: pipe s. Expert Rev Hematol. 2018 Nov;11(11):835-846. doi: 10.1080/17474086.2018.1531701. Epub 2018 Oct 10. Expert Rev Hematol. 2018. PMID: 30278802 Review.

5

What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Janbain M, Pipe S. Janbain M, et al. Among authors: pipe s. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):648-649. doi: 10.1182/asheducation-2016.1.648. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913541 Free PMC article. Review.

6

Consideration in hemophilia therapy selection.

Pipe S. Pipe S. Semin Hematol. 2006 Apr;43(2 Suppl 3):S23-7. doi: 10.1053/j.seminhematol.2006.02.002. Semin Hematol. 2006. PMID: 16631824 Review.

7

The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Hay CR, DiMichele DM; International Immune Tolerance Study. Hay CR, et al. Blood. 2012 Feb 9;119(6):1335-44. doi: 10.1182/blood-2011-08-369132. Epub 2011 Nov 18. Blood. 2012. PMID: 22101900 Free article. Clinical Trial.

8

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B; GENEr8-1 Trial Group. Ozelo MC, et al. Among authors: pipe sw. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708. N Engl J Med. 2022. PMID: 35294811 Clinical Trial.

9

Visions in haemophilia care.

Pipe S. Pipe S. Thromb Res. 2009 Dec;124 Suppl 2:S2-5. doi: 10.1016/S0049-3848(09)70156-2. Thromb Res. 2009. PMID: 20109652 Review.

10

Innovations in coagulation: improved options for treatment of hemophilia A and B.

Pabinger-Fasching I, Pipe S. Pabinger-Fasching I, et al. Among authors: pipe s. Thromb Res. 2013 Mar;131 Suppl 2:S1. doi: 10.1016/S0049-3848(13)00051-0. Thromb Res. 2013. PMID: 23537720 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190 results

Search Page